| Compound | B7-33 |
|---|---|
| Category | H2-relaxin mimetic peptide |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
B7-33 is catalogued here as a h2-relaxin mimetic peptide and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A single-chain mimetic of the H2 relaxin receptor (RXFP1) studied for antifibrotic effects in animal models of cardiovascular and renal disease.
Mechanism of Action
B7-33 activates RXFP1 in a biased fashion, mimicking selected downstream signaling of relaxin — a hormone associated with tissue remodeling and anti-fibrotic pathways — without replicating its full hormonal profile.
Research and Evidence
Published evidence is limited to rodent and cell models of fibrosis and vascular injury. No human trials have been reported.
Safety and Side Effects
No human safety data exist; the compound is a research tool rather than a therapeutic candidate in clinical testing.
Frequently Asked Questions
What is the evidence tier of B7-33?
B7-33 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is B7-33 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for B7-33?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for B7-33 studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.